Personalized cancer vaccines can prime the immune system against cancer, but scientists are still learning how the route of vaccination influences the T-cell response. See how #singlecell insights are helping researchers understand this treatment approach. 10xgenomics.com/blog/understan…

#SARSCoV2_Infection | Immune Correlates of Protection by mRNA-1273 Immunization in Nonhuman Primates | Bob Seder NIAID News bioRxiv buff.ly/3tJDePD

I gave a seminar today and got absolutely butchered by the toughest crowd of immunologists at NIH, but then someone emailed me and said I handled it well and am their role model... totally made my day!!! 🥲🥲🥲

A monoclonal antibody appeared to show some efficacy in a small group of patients with malaria who had never been exposed to the disease, reported Robert Seder, MD, of NIAID News, in NEJM. By @mms_walker, MedPage Infectious Disease. #IDtwitter bit.ly/3CJTpBx

We are delighted to announce the acquisition of @AvideaTech. Avidea’s complementary technology platforms and expertise in precision immunotherapies and synthetic nanoparticle design bring synergies in R&D and new commercial opportunities to Vaccitech. bit.ly/3GKlg5L

The hometown looking gorgeous.

First in-person conference in two years!

This video by Alex Ritter, PhD shows an immune cell called a T cell (purple) approaching and attaching to a cancer cell (teal). The T cell tries to kill the cancer cell by secreting a toxin (red wave), but the cancer cell survives. Follow this thread to see how this battle ends. ⬇️

Along with TurleyLab, Sören Müller, and our team Genentech, I'm thrilled to share our newest work out now in nature: nature.com/articles/s4158…. We show depleting TGFβ-driven LRRC15+ cancer-associated fibroblasts (CAFs) augments tumor control and response to immunotherapy🧵1/

Our “Vax-Innate” paper is now online! Optimizing T cells + TME + Timing = Tumor regression using a cancer vaccine. THANKS to co-authors, reviewers and Cell for this opportunity to share our work. authors.elsevier.com/c/1f~D4L7PXiqSW

#InterferonPower & #LocationLocationLocation Cell! Systemic, not local, immunization with an anti-tumor nanoparticle vaccine suppresses tumors by remodeling the tumor microenvironment via type I IFNs that reduce immunosuppressive monocytes! Doi.org/10.1016/j.cell…

Today we announced the publication of research in Cell Press that demonstrates anti-tumor activity of the SNAPvax™ platform in a preclinical model achieved through IV administration. Doing this activates 2 pathways essential for tumor regression. View:bit.ly/3TWvxCc

Very stimulating study🔥 showing that to effectively treat cancer, in conjunction with activation of T cell immunity, myeloid populations in the TME will need to be robustly activated. sciencedirect.com/science/articl…

Thank you ACIR for featuring our work! Their graphical abstracts are always so good :)

News: Experimental cancer vaccine shows promise in animal studies dlvr.it/ScYN6r

Congrats Andrei Andrei Ramirez and team!

A Perspective by Seder and colleagues considers present and historical paradigms of therapeutic cancer vaccines and describes a new approach, termed “Vax-Innate”, to generate robust tumor-specific T cell responses.nature.com/articles/s4157…

REVIEW Nature Rev Immunol Faezzah Baharom Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumor microenvironment nature.com/articles/s4157…